department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Kymera Therapeutics, Inc. ($KYMR) · pharmadog

PUBLIC COMPANY

$KYMRKymera Therapeutics, Inc.

Watertown, MA, USupdated 3h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

1

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 2

Eosinophilic Asthma

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

view all catalysts →

🐶 Hiring Signal

22 open roles at Kymera Therapeutics, Inc. →

Where Kymera Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaImmunology & Inflammation 22

departmentR&D / Discovery 4 IT & Engineering 3 Clinical 3 Biostatistics / Data 2 Quality 1 Regulatory 1

News

no news has mentioned this company yet

identifiers

ticker

$KYMR

SEC CIK

0001815442

country

US

source

sec_tickers

top tags

Asthma1 Dermatology1 Pulmonology1

mentioned in

0news items

entity-linker matched

Kymera Therapeutics, Inc. earnings

Kymera Therapeutics, Inc.

$KYMR115.92+2.12%

Active trials

phase2A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitisrecruitingn=200
phase2A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthmarecruitingn=264
phase1First-in-human Study of Orally Administered KT-579 in Healthy Adult Participantsrecruitingn=96
phase1Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)completedn=22
phase1First-in-human Study of Orally Administered KT-621 in Healthy Adult Participantscompletedn=118
phase1Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumorscompletedn=56
phase1Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumorscompletedn=52
phase1Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHLcompletedn=7

more trials →

Insider activity

source: SEC Form 4

90d open-market buys

$0

0 transactions

90d open-market sells

$3.03M

15 transactions

net (buys − sells)

−$3.03M

non-derivative only

open-market buys + sells

Apr 22, 26SELLBooth Bruce· 5,900 sh @ $89.96−$531K↗
Apr 22, 26SELLChadwick Jeremy G· Chief Operating Officer300 sh @ $90.00−$27K↗
Apr 22, 26SELLBooth Bruce· 88 sh @ $90.08−$8K↗
Apr 22, 26SELLBooth Bruce· 12 sh @ $90.08−$1K↗
Apr 15, 26SELLBooth Bruce· 2,750 sh @ $90.10−$248K↗
Apr 15, 26SELLBooth Bruce· 2,200 sh @ $89.95−$198K↗
Apr 15, 26SELLChadwick Jeremy G· Chief Operating Officer1,300 sh @ $90.00−$117K↗
Apr 15, 26SELLBooth Bruce· 385 sh @ $90.10−$35K↗
Apr 14, 26SELLChadwick Jeremy G· Chief Operating Officer5,251 sh @ $90.00−$473K↗
Apr 14, 26SELLBooth Bruce· 4,159 sh @ $89.97−$374K↗
Apr 14, 26SELLGoodman Noah· Chief Business Officer1,347 sh @ $90.00−$121K↗
Apr 10, 26SELLGoodman Noah· Chief Business Officer2,000 sh @ $87.35−$175K↗
Apr 9, 26SELLGoodman Noah· Chief Business Officer3,094 sh @ $86.62−$268K↗
Apr 9, 26SELLGoodman Noah· Chief Business Officer2,670 sh @ $87.11−$233K↗
Apr 9, 26SELLGoodman Noah· Chief Business Officer2,500 sh @ $89.00−$223K↗
Apr 1, 26SELLChadwick Jeremy G· Chief Operating Officer13,540 sh @ $85.41−$1.16M↗
Apr 1, 26SELLRidloff Elena· director3,400 sh @ $85.19−$290K↗
Apr 1, 26SELLRidloff Elena· director1,200 sh @ $86.05−$103K↗
Apr 1, 26SELLChadwick Jeremy G· Chief Operating Officer1,100 sh @ $86.05−$95K↗
Mar 31, 26SELLChadwick Jeremy G· Chief Operating Officer7,600 sh @ $85.38−$649K↗

$KYMR115.92+2.12%

Data sources

last refreshed 50m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?